As Novo Nordisk’s injectable GLP-1 receptor agonist drug Ozempic/Wegovy (semaglutide) and Eli Lilly’s dual GIP/GLP-1 agonist Mounjaro (tirzepatide) revolutionize obesity and type 2 diabetes treatment, Pfizer is convinced it can seize a slice of the future multi-billion-dollar market with a more convenient oral challenger.
The firm has previously estimated that the oral GLP-1 market could reach nearly $30bn by 2030 (covering both type 2 diabetes and obesity), or around a third of the entire GLP-1 market by 2030